{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:06:37Z","timestamp":1790957197633,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"UCB Pharma and Amgen Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00198-024-07049-w","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T04:07:37Z","timestamp":1712203657000},"page":"1195-1204","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5086-6940","authenticated-orcid":false,"given":"J.","family":"Lane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8712-7199","authenticated-orcid":false,"given":"B.","family":"Langdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1568-9560","authenticated-orcid":false,"given":"M.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kurth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2143-7506","authenticated-orcid":false,"given":"M.","family":"Oates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Timoshanko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1636-7240","authenticated-orcid":false,"given":"Z.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1427-7839","authenticated-orcid":false,"given":"C.","family":"Libanati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4554-6616","authenticated-orcid":false,"given":"F.","family":"Cosman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,4]]},"reference":[{"key":"7049_CR1","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00198-008-0742-8","volume":"20","author":"LJ Melton 3rd","year":"2009","unstructured":"Melton LJ 3rd, Kearns AE, Atkinson EJ, Bolander ME, Achenbach SJ, Huddleston JM, Therneau TM, Leibson CL (2009) Secular trends in hip fracture incidence and recurrence. Osteoporos Int 20:687\u2013694. https:\/\/doi.org\/10.1007\/s00198-008-0742-8","journal-title":"Osteoporos Int"},{"key":"7049_CR2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.bone.2004.03.024","volume":"35","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johnell O, De Laet C et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375\u2013382. https:\/\/doi.org\/10.1016\/j.bone.2004.03.024","journal-title":"Bone"},{"key":"7049_CR3","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s00198-018-4502-0","volume":"29","author":"JA Kanis","year":"2018","unstructured":"Kanis JA, Johansson H, Od\u00e9n A et al (2018) Characteristics of recurrent fractures. Osteoporos Int 29:1747\u20131757. https:\/\/doi.org\/10.1007\/s00198-018-4502-0","journal-title":"Osteoporos Int"},{"key":"7049_CR4","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s001980050218","volume":"10","author":"LJ Melton 3rd","year":"1999","unstructured":"Melton LJ 3rd, Atkinson EJ, Cooper C, O\u2019Fallon WM, Riggs BL (1999) Vertebral fractures predict subsequent fractures. Osteoporos Int 10:214\u2013221. https:\/\/doi.org\/10.1007\/s001980050218","journal-title":"Osteoporos Int"},{"key":"7049_CR5","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00198-016-3868-0","volume":"28","author":"H Johansson","year":"2017","unstructured":"Johansson H, Siggeirsd\u00f3ttir K, Harvey NC, Od\u00e9n A, Gudnason V, McCloskey E, Sigurdsson G, Kanis JA (2017) Imminent risk of fracture after fracture. Osteoporos Int 28:775\u2013780. https:\/\/doi.org\/10.1007\/s00198-016-3868-0","journal-title":"Osteoporos Int"},{"key":"7049_CR6","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1007\/s11914-018-0487-z","volume":"16","author":"AD Schnell","year":"2018","unstructured":"Schnell AD, Curtis JR, Saag KG (2018) Importance of recent fracture as predictor of imminent fracture risk. Curr Osteoporos Rep 16:738\u2013745. https:\/\/doi.org\/10.1007\/s11914-018-0487-z","journal-title":"Curr Osteoporos Rep"},{"key":"7049_CR7","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1007\/s00198-022-06473-0","volume":"33","author":"RMY Wong","year":"2022","unstructured":"Wong RMY, Wong PY, Liu C, Wong HW, Chung YL, Chow SKH, Law SW, Cheung WH (2022) The imminent risk of a fracture-existing worldwide data: a systematic review and meta-analysis. Osteoporos Int 33:2453\u20132466. https:\/\/doi.org\/10.1007\/s00198-022-06473-0","journal-title":"Osteoporos Int"},{"key":"7049_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1080\/00325481.2022.2069582","volume":"134","author":"MR McClung","year":"2022","unstructured":"McClung MR, Rothman MS, Lewiecki EM, Hanley DA, Harris ST, Miller PD, Kendler DL (2022) The role of osteoanabolic agents in the management of patients with osteoporosis. Postgrad Med 134:541\u2013551. https:\/\/doi.org\/10.1080\/00325481.2022.2069582","journal-title":"Postgrad Med"},{"key":"7049_CR9","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s00198-015-3098-x","volume":"26","author":"C Klop","year":"2015","unstructured":"Klop C, Gibson-Smith D, Elders PJM, Welsing PMJ, Leufkens HGM, Harvey NC, Bijlsma JWJ, van Staa TP, de Vries F (2015) Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000\u20132010. Osteoporos Int 26:1919\u20131928. https:\/\/doi.org\/10.1007\/s00198-015-3098-x","journal-title":"Osteoporos Int"},{"key":"7049_CR10","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s00198-019-05066-8","volume":"30","author":"PK Kristensen","year":"2019","unstructured":"Kristensen PK, Ehrenstein V, Shetty N, Pedersen AB (2019) Use of anti-osteoporosis medication dispensing by patients with hip fracture: could we do better? Osteoporos Int 30:1817\u20131825. https:\/\/doi.org\/10.1007\/s00198-019-05066-8","journal-title":"Osteoporos Int"},{"key":"7049_CR11","doi-asserted-by":"publisher","first-page":"215145932098036","DOI":"10.1177\/2151459320980369","volume":"11","author":"DW Barton","year":"2020","unstructured":"Barton DW, Smith CT, Piple AS, Moskal SA, Carmouche JJ (2020) Timing of bisphosphonate initiation after fracture: what does the data really say? Geriatr Orthop Surg Rehabil 11:2151459320980369. https:\/\/doi.org\/10.1177\/2151459320980369","journal-title":"Geriatr Orthop Surg Rehabil"},{"key":"7049_CR12","doi-asserted-by":"publisher","first-page":"1759720x2210835","DOI":"10.1177\/1759720x221083541","volume":"14","author":"G Adami","year":"2022","unstructured":"Adami G, Fassio A, Gatti D, Viapiana O, Benini C, Danila MI, Saag KG, Rossini M (2022) Osteoporosis in 10 years time: a glimpse into the future of osteoporosis. Ther Adv Musculoskelet Dis 14:1759720x221083541. https:\/\/doi.org\/10.1177\/1759720x221083541","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"7049_CR13","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/jbmr.3182","volume":"32","author":"N Binkley","year":"2017","unstructured":"Binkley N, Blank RD, Leslie WD, Lewiecki EM, Eisman JA, Bilezikian JP (2017) Osteoporosis in crisis: it\u2019s time to focus on fracture. J Bone Miner Res 32:1391\u20131394. https:\/\/doi.org\/10.1002\/jbmr.3182","journal-title":"J Bone Miner Res"},{"key":"7049_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1749-799x-9-45","volume":"9","author":"D Xue","year":"2014","unstructured":"Xue D, Li F, Chen G, Yan S, Pan Z (2014) Do bisphosphonates affect bone healing? A meta-analysis of randomized controlled trials. J Orthop Surg Res 9:45. https:\/\/doi.org\/10.1186\/1749-799x-9-45","journal-title":"J Orthop Surg Res"},{"key":"7049_CR15","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.injury.2018.04.016","volume":"49","author":"DJ Hak","year":"2018","unstructured":"Hak DJ (2018) The biology of fracture healing in osteoporosis and in the presence of anti-osteoporotic drugs. Injury 49:1461\u20131465. https:\/\/doi.org\/10.1016\/j.injury.2018.04.016","journal-title":"Injury"},{"issue":"Suppl 1","key":"7049_CR16","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/s0020-1383(16)30015-8","volume":"47","author":"SL Kates","year":"2016","unstructured":"Kates SL, Ackert-Bicknell CL (2016) How do bisphosphonates affect fracture healing? Injury 47(Suppl 1):S65-68. https:\/\/doi.org\/10.1016\/s0020-1383(16)30015-8","journal-title":"Injury"},{"key":"7049_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00198-018-4687-2","volume":"30","author":"DL Kendler","year":"2019","unstructured":"Kendler DL, Chines A, Brandi ML, Papapoulos S, Lewiecki EM, Reginster JY, Mu\u00f1oz Torres M, Wang A, Bone HG (2019) The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies. Osteoporos Int 30:71\u201378. https:\/\/doi.org\/10.1007\/s00198-018-4687-2","journal-title":"Osteoporos Int"},{"key":"7049_CR18","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1302\/2058-5241.4.180018","volume":"4","author":"S Tanaka","year":"2019","unstructured":"Tanaka S (2019) Molecular understanding of pharmacological treatment of osteoporosis. EFORT Open Rev 4:158\u2013164. https:\/\/doi.org\/10.1302\/2058-5241.4.180018","journal-title":"EFORT Open Rev"},{"key":"7049_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/jbmr.173","volume":"26","author":"D Padhi","year":"2011","unstructured":"Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19\u201326. https:\/\/doi.org\/10.1002\/jbmr.173","journal-title":"J Bone Miner Res"},{"key":"7049_CR20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/jbmr.3622","volume":"34","author":"EM Lewiecki","year":"2019","unstructured":"Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, Ebeling PR, Adachi JD, Miyauchi A, Gielen E, Milmont CE, Libanati C, Grauer A (2019) One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study. J Bone Miner Res 34:419\u2013428. https:\/\/doi.org\/10.1002\/jbmr.3622","journal-title":"J Bone Miner Res"},{"key":"7049_CR21","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948","journal-title":"N Engl J Med"},{"key":"7049_CR22","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMoa1708322","journal-title":"N Engl J Med"},{"key":"7049_CR23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00198-018-4732-1","volume":"30","author":"A Balasubramanian","year":"2019","unstructured":"Balasubramanian A, Zhang J, Chen L, Wenkert D, Daigle SG, Grauer A, Curtis JR (2019) Risk of subsequent fracture after prior fracture among older women. Osteoporos Int 30:79\u201392. https:\/\/doi.org\/10.1007\/s00198-018-4732-1","journal-title":"Osteoporos Int"},{"key":"7049_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.11005\/jbm.2020.27.1.15","volume":"27","author":"YH Shin","year":"2020","unstructured":"Shin YH, Shin WC, Kim JW (2020) Effect of osteoporosis medication on fracture healing: an evidence based review. J Bone Metab 27:15\u201326. https:\/\/doi.org\/10.11005\/jbm.2020.27.1.15","journal-title":"J Bone Metab"},{"key":"7049_CR25","doi-asserted-by":"publisher","first-page":"437","DOI":"10.4055\/cios.2016.8.4.437","volume":"8","author":"JB Seo","year":"2016","unstructured":"Seo JB, Yoo JS, Ryu JW, Yu KW (2016) Influence of early bisphosphonate administration for fracture healing in patients with osteoporotic proximal humerus fractures. Clin Orthop Surg 8:437\u2013443. https:\/\/doi.org\/10.4055\/cios.2016.8.4.437","journal-title":"Clin Orthop Surg"},{"key":"7049_CR26","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1302\/0301-620x.94b7.29079","volume":"94","author":"TY Kim","year":"2012","unstructured":"Kim TY, Ha YC, Kang BJ, Lee YK, Koo KH (2012) Does early administration of bisphosphonate affect fracture healing in patients with intertrochanteric fractures? J Bone Joint Surg Br 94:956\u2013960. https:\/\/doi.org\/10.1302\/0301-620x.94b7.29079","journal-title":"J Bone Joint Surg Br"},{"key":"7049_CR27","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1007\/s00198-010-1473-1","volume":"22","author":"C Col\u00f3n-Emeric","year":"2011","unstructured":"Col\u00f3n-Emeric C, Nordsletten L, Olson S et al (2011) Association between timing of zoledronic acid infusion and hip fracture healing. Osteoporos Int 22:2329\u20132336. https:\/\/doi.org\/10.1007\/s00198-010-1473-1","journal-title":"Osteoporos Int"},{"key":"7049_CR28","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.2106\/jbjs.19.01008","volume":"102","author":"M Bhandari","year":"2020","unstructured":"Bhandari M, Schemitsch EH, Karachalios T et al (2020) Romosozumab in skeletally mature adults with a fresh unilateral tibial diaphyseal fracture: a randomized phase-2 study. J Bone Joint Surg Am 102:1416\u20131426. https:\/\/doi.org\/10.2106\/jbjs.19.01008","journal-title":"J Bone Joint Surg Am"},{"key":"7049_CR29","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2106\/jbjs.19.00790","volume":"102","author":"EH Schemitsch","year":"2020","unstructured":"Schemitsch EH, Miclau T, Karachalios T et al (2020) A randomized, placebo-controlled study of romosozumab for the treatment of hip fractures. J Bone Joint Surg Am 102:693\u2013702. https:\/\/doi.org\/10.2106\/jbjs.19.00790","journal-title":"J Bone Joint Surg Am"},{"key":"7049_CR30","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.2106\/jbjs.k.00774","volume":"94","author":"S Adami","year":"2012","unstructured":"Adami S, Libanati C, Boonen S et al (2012) Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. J Bone Joint Surg Am 94:2113\u20132119. https:\/\/doi.org\/10.2106\/jbjs.k.00774","journal-title":"J Bone Joint Surg Am"},{"key":"7049_CR31","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1007\/s00198-021-05847-0","volume":"32","author":"K Eastman","year":"2021","unstructured":"Eastman K, Gerlach M, Piec I, Greeves J, Fraser W (2021) Effectiveness of parathyroid hormone (PTH) analogues on fracture healing: a meta-analysis. Osteoporos Int 32:1531\u20131546. https:\/\/doi.org\/10.1007\/s00198-021-05847-0","journal-title":"Osteoporos Int"},{"key":"7049_CR32","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Col\u00f3n-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799\u20131809. https:\/\/doi.org\/10.1056\/NEJMoa074941","journal-title":"N Engl J Med"},{"key":"7049_CR33","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s00198-005-2025-y","volume":"17","author":"SW Veitch","year":"2006","unstructured":"Veitch SW, Findlay SC, Hamer AJ, Blumsohn A, Eastell R, Ingle BM (2006) Changes in bone mass and bone turnover following tibial shaft fracture. Osteoporos Int 17:364\u2013372. https:\/\/doi.org\/10.1007\/s00198-005-2025-y","journal-title":"Osteoporos Int"},{"key":"7049_CR34","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s001980050246","volume":"10","author":"BM Ingle","year":"1999","unstructured":"Ingle BM, Hay SM, Bottjer HM, Eastell R (1999) Changes in bone mass and bone turnover following distal forearm fracture. Osteoporos Int 10:399\u2013407. https:\/\/doi.org\/10.1007\/s001980050246","journal-title":"Osteoporos Int"},{"key":"7049_CR35","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s12018-018-9253-0","volume":"16","author":"B Osipov","year":"2018","unstructured":"Osipov B, Emami AJ, Christiansen BA (2018) Systemic bone loss after fracture. Clin Rev Bone Miner Metab 16:116\u2013130. https:\/\/doi.org\/10.1007\/s12018-018-9253-0","journal-title":"Clin Rev Bone Miner Metab"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-024-07049-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-024-07049-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-024-07049-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T06:06:14Z","timestamp":1719468374000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-024-07049-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,4]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["7049"],"URL":"https:\/\/doi.org\/10.1007\/s00198-024-07049-w","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,4]]},"assertion":[{"value":"20 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All the results presented in this article are in aggregate form, and no personally identifiable information was used for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Joseph Lane received grants from Radius and Merck; served on the speakers\u2019 bureau for UCB Pharma. Bente Langdahl received fees and honoraria for lectures and advice from Amgen, Gedeon\u00a0Richter, Gilead, and UCB Pharma; research grants for Aarhus University Hospital from Amgen Inc. and Novo Nordisk. Michael Stone received payments for lectures and Advisory Boards for UCB, Amgen, and Gedeon Richter. Andreas Kurth served as a consultant for Amgen, UCB, Eli Lilly, and Theramax; served on the speakers\u2019 bureaus for Amgen, UCB, Eli Lilly, and Theramax. Mary Oates is an employee and stockholder of Amgen. Jen Timoshanko is an employee and shareholder of UCB Pharma. Zhenxun Wang is an employee and stockholder of Amgen. Cesar Libanati is an employee and shareholder of UCB Pharma. Felicia Cosman received institutional grants and research support from Amgen and from Radius Health; served as a consultant for Amgen, Biocon, Enterabio, Pfizer\/Myovant and Radius Health; served on the speakers\u2019 bureaus for Amgen and Radius Health.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}